2021 Revenues ($USD) : $28,318,400,000
2021 R&D spend : $7,025,900,000
2021 Number of Employees : 35,238
Fiscal Year End : 12/31/2021
Leader : CEO David Ricks

Founded in 1876, Eli Lilly had revenue growth of 10% for 2021, excluding COVID-19 antibodies. Growth drivers include Trulicity (dulaglutide), Taltz (ixekizumab), Jardiance (empagliflozin), Verzenio (abemaciclib) and Olumiant (Baricitinib). The Indianapolis-based company makes drugs for diabetes, oncology, immunology, neurosciences and other therapies, including COVID-19 treatment therapies. Lilly’s COVID-19 antibody bebtelovimab has so far demonstrated its resilience to emerging SARS-CoV-2 variants, including the BA.2 subvariant of the omicron variant. Also in 2021, the company noted continued progress with its five top molecules in its pipeline, which include tirzepatide, donanemab, pirtobrutinib, mirikizumab and lebrikizumab. —BB